Darrell Mease, MD
Family Medicine · Jay, OKNPI 1952377442
Payments from drug & device makers
Across 163 payments — averaging $14.92 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Amgen$272
- GSK$271
- Astellas Pharma US Inc$192
- AbbVie$184
- Novo Nordisk$165
- AstraZeneca$149
- plus $1K from 27 others
What the payments were for
- Food & beverage$2,27393%
- Education$1597%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Amgen | 13 | $272 |
| GSK | 24 | $271 |
| Astellas Pharma US Inc | 9 | $192 |
| AbbVie(2 entities) | 10 | $184 |
| Novo Nordisk | 16 | $165 |
| AstraZeneca | 11 | $149 |
| Sunovion Pharmaceuticals Inc. | 15 | $108 |
| Boehringer Ingelheim | 8 | $108 |
| Sumitomo Pharma America, Inc. | 5 | $106 |
| Avanir Pharmaceuticals, Inc. | 7 | $97 |
| Mylan Specialty L.p. | 6 | $95 |
| Merck | 4 | $88 |
| Pfizer | 5 | $69 |
| Johnson & Johnson | 4 | $54 |
| Vanda Pharmaceuticals Inc. | 2 | $50 |
| UCB, Inc. | 3 | $44 |
| Smith+Nephew | 2 | $40 |
| Novartis | 2 | $37 |
| SK Life Science, Inc. | 1 | $32 |
| Teva Pharmaceuticals USA, Inc. | 2 | $25 |
| Lundbeck LLC | 1 | $24 |
| Lilly USA, LLC | 1 | $24 |
| Exact Sciences | 1 | $23 |
| Viatris Specialty LLC | 1 | $22 |
| Medtronic | 1 | $21 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $19 |
| Regeneron Healthcare Solutions, Inc. | 1 | $19 |
| OPKO Pharmaceuticals, LLC | 1 | $19 |
| Otsuka America Pharmaceutical, Inc. | 1 | $17 |
| Axsome Therapeutics, Inc. | 1 | $16 |
| Zyla Life Sciences, Inc. | 1 | $15 |
| Supernus Pharmaceuticals, Inc. | 1 | $14 |
| Phathom Pharmaceuticals, Inc. | 1 | $14 |
How this compares
$2,432 in reported general payments places this provider in the 75th percentile of 1,730 family medicine providers in Oklahoma.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 133 | $153,355 |
| EliquisApixaban | 222 | $152,736 |
| MounjaroTirzepatide | 100 | $149,015 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 105 | $108,559 |
| TrulicityDulaglutide | 93 | $103,489 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 125 | $96,919 |
| Enbrel SureclickEtanercept | 12 | $89,903 |
| LinzessLinaclotide | 81 | $79,700 |
| Xeljanz XrTofacitinib Citrate | 12 | $73,032 |
| XareltoRivaroxaban | 70 | $63,902 |
| RexultiBrexpiprazole | 41 | $47,891 |
| JardianceEmpagliflozin | 48 | $43,515 |
| SymbicortBudesonide/Formoterol Fumarate | 102 | $36,629 |
| VraylarCariprazine Hcl | 25 | $36,358 |
| JanuviaSitagliptin Phosphate | 49 | $35,267 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro, Trulicity | $24 | $252,504193 claims |
| AstraZenecaBreztri Aerosphere, Symbicort, Farxiga, Brilinta | $149 | $163,412276 claims |
| Novo NordiskOzempic | $165 | $153,355133 claims |
| PfizerEliquis | $69 | $152,736222 claims |
| AbbVieLinzess, Vraylar | $184 | $116,058106 claims |
| GSKTrelegy Ellipta | $271 | $108,559105 claims |
| Johnson & JohnsonXarelto | $54 | $63,90270 claims |
| Boehringer IngelheimJardiance, Trijardy Xr | $108 | $58,83566 claims |
| MerckJanuvia, Janumet Xr, Dulera | $88 | $54,89689 claims |
| Otsuka America Pharmaceutical, Inc.Rexulti | $17 | $47,89141 claims |
| Astellas Pharma US IncMyrbetriq | $192 | $34,06653 claims |
| NovartisEntresto | $37 | $25,89935 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 1,730 family medicine providers in Oklahoma.
Other family medicine in Jay
- Carl GriffinOklahoma City$28.2M
- Lisa ConneryNorman$15.6M
- Kyle RicknerYukon$14.7M
- Robert LockwoodYukon$8.6M
- Steven CoxNorman$6.9M
- Alexander FrankOklahoma City$3.1M
- Rachel AndersonNorman$2.8M
- Robert WestcottLindsay$1.6M
- Charles LunnOklahoma City$1.4M
- Jeffrey ChasteenTulsa$820K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.